Endonovo Therapeutics (ENDV) 10-Q 13 Aug 18 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2018	Aug. 13, 2018
Document And Entity Information
Entity Registrant Name	ENDONOVO THERAPEUTICS, INC.
Entity Central Index Key	1,528,172
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		366,118,767
Trading Symbol	ENDV
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Current assets:
Cash	$ 67,622	$ 90,173
Accounts receivable	10,073
Prepaid expenses and other current assets	21,000	21,000
Total current assets	98,695	111,173
Property Plant and Equipment, net	8,754	1,064
Patents, net	4,176,545	4,500,000
Total assets	4,283,994	4,612,237
Current Liabilities
Accounts payable and accrued expenses	3,069,985	2,714,041
Short term advances		20,323
Notes payable, net of discounts of $1,355,554 as of June 30, 2018 and $2,624,984 as of December 31, 2017	5,863,469	4,461,160
Notes payable - related parties	270,000	270,000
Derivative liability	3,119,924	5,939,600
Current portion of long term loan		4,221
Total current liabilities	12,323,378	13,409,345
Series C preferred stock liability, net of discounts of $115,596 at June 30, 2018 and $101,808 as of December 31, 2017	921,904	598,192
Acquisition payable	155,000	155,000
Total liabilities	13,400,282	14,162,537
COMMITMENTS AND CONTINGENCIES
Shareholders' deficit
Super AA super voting preferred stock, $0.001 par value; 1,000,000 authorized and 5,000 and 5,000 issued and outstanding at June 30, 2018 and December 31, 2017	5	5
Series B convertible preferred stock, $0.0001 par value; 50,000 shares authorized, 1,350 and 0 issued and outstanding at June 30, 2018 and December 31, 2017	1
Common stock, $0.0001 par value; 500,000,000 shares authorized; 356,268,939 and 316,951,712 shares issued and outstanding as of June 30, 2018 and December 31, 2017	35,625	31,692
Additional paid-in capital	21,903,851	19,604,016
Stock subscriptions	(1,570)	(1,570)
Accumulated deficit	(31,054,200)	(29,184,443)
Total shareholders' deficit	(9,116,288)	(9,550,300)
Total liabilities and shareholders' deficit	$ 4,283,994	$ 4,612,237

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Discounts on current notes payable	$ 1,355,554	$ 2,624,984
Super AA super voting preferred stock, par value	$ 0.001	$ 0.001
Super AA super voting preferred stock, shares authorized	1,000,000	1,000,000
Super AA super voting preferred stock, shares issued	5,000	5,000
Super AA super voting preferred stock, shares outstanding	5,000	5,000
Series B convertible preferred stock, par value	$ 0.0001	$ 0.0001
Series B convertible preferred stock, shares authorized	50,000	50,000
Series B convertible preferred stock, shares issued	1,350	0
Series B convertible preferred stock, shares outstanding	1,350	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	356,268,939	316,951,712
Common stock, shares outstanding	356,268,939	316,951,712
Series C Preferred Stock [Member]
Series C preferred stock liability, net of discounts	$ 115,596	$ 101,808

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Income Statement [Abstract]
Revenue	$ 12,854		$ 19,826
Cost of revenue	550		550
Gross profit	12,304		19,276
Operating expenses	828,959	2,177,789	2,111,275	2,735,301
Loss from operations	(816,655)	(2,177,789)	(2,091,999)	(2,735,301)
Other income (expense)
Change in fair value of derivative liability	647,121	3,035,470	2,461,179	(2,400,778)
Gain (loss) on settlement of debt	143,517	2,326,289	258,345	2,233,656
Interest expense, net	(1,224,823)	(1,325,981)	(2,497,282)	(3,004,564)
Other income (expense)	(434,185)	4,035,778	222,242	(3,171,686)
Income (loss) before income taxes	(1,250,840)	1,857,989	(1,869,757)	(5,906,987)
Provision for income taxes
Net income (loss)	$ (1,250,840)	$ 1,857,989	$ (1,869,757)	$ (5,906,987)
Basic net income (loss) per share	$ 0	$ 0.01	$ (0.01)	$ (0.03)
Basic weighted average common shares outstanding	347,939,531	234,997,177	337,779,860	198,404,131
Diluted income (loss) per share	$ 0	$ 0.01	$ (0.01)	$ (0.03)
Diluted weighted average common shares outstanding	347,939,531	330,801,266	337,779,860	198,404,131

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Operating activities:
Net loss	$ (1,869,757)	$ (5,906,987)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization expense	324,734	7,381
Fair value of equity issued for services	5,460	254,946
Stock based compensation		1,000,090
Loss (gain) on extinguishment of debt	(258,345)	(2,233,656)
Amortization of note discount and original issue discount	1,930,223	895,322
Amortization of discount on Series C Preferred stock liability	32,192
Non-cash interest expense	134,952	1,994,526
Non-cash value of warrant issued for services	380,750
Change in fair value of derivative liability	(2,461,179)	2,400,778
Changes in assets and liabilities:
Accounts receivable	(10,073)
Prepaid expenses and other current assets		76,321
Accounts payable and accrued expenses	458,682	163,440
Net cash used in operating activities	(1,332,361)	(1,347,839)
Investing activities:
Acquisition of property and equipment	(8,969)
Net cash used in investing activities	(8,969)
Financing activities:
Proceeds from the issuance of notes payable	825,000	878,500
Proceeds from related party short-term advances	65,000	12,650
Repayments on related parties short term advances	(87,000)	(11,500)
Proceeds from issuance of common stock and units	60,000	472,749
Payment against long term loan	(4,221)	(6,151)
Payment against notes payable	(12,500)	(30,000)
Proceeds from issuance of redeemable shares	337,500
Proceeds from issuance of preferred stock	135,000
Net cash provided by financing activities	1,318,779	1,316,248
Net decrease in cash	(22,551)	(31,591)
Cash, beginning of year	90,173	55,533
Cash, end of period	67,622	23,942
Supplemental disclosure of cash flow information:
Cash paid for interest	70,220	8,711
Cash paid for income taxes
Non Cash Investing and Financing Activities:
Conversion of notes payable and accrued interest to common stock	824,053	761,810
Reduction in note payable and accrued interest as result of settlement	82,000
Common stock issued on settlement of debt		185,945
Notes payable and accrued interest exchanged for common stock units		$ 66,367

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Shareholders' Deficit (Unaudited) - 6 months ended Jun. 30, 2018 - USD ($)	Series AA Preferred Stock [Member]	Series B Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-In Capital [Member]	Common Stock Subscription Receivable [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2017	$ 5		$ 31,692	$ 19,604,016	$ (1,570)	$ (29,184,443)	$ (9,550,300)
Balance, shares at Dec. 31, 2017	5,000		316,951,712
Private placement units issued for cash			$ 156	59,844			60,000
Private placement units issued for cash, shares			1,561,950
Preferred stock issued for cash		$ 1		134,999			135,000
Preferred stock issued for cash, shares		1,350
Share issued for services			$ 13	5,447			$ 5,460
Share issued for services, shares			125,000				125,000
Shares issued with lock-up agreements			$ 2	1,044			$ 1,046
Shares issued with lock-up agreements, shares			17,003
Shares issued for conversion of notes payable and accrued interest			$ 3,423	1,464,641			1,468,064
Shares issued for conversion of notes payable and accrued interest, shares			34,225,740
Valuation of warrants issued with Preferred Series C				45,980			45,980
Valuation of warrants issued for services				380,750			380,750
Valuation of warrants issued with note payable				71,521			71,521
Shares issued for commitment fees			$ 339	116,192			$ 116,531
Shares issued for commitment fees, shares			3,387,534				3,387,534
Valuation of warrants issued for extension of notes				19,417			$ 19,417
Net loss						(1,869,757)	(1,869,757)
Balance at Jun. 30, 2018	$ 5	$ 1	$ 35,625	$ 21,903,851	$ (1,570)	$ (31,054,200)	$ (9,116,288)
Balance, shares at Jun. 30, 2018	5,000	1,350	366,118,767

Organization and Nature of Busi

Organization and Nature of Business	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Business	Note 1 - Organization and Nature of Business Endonovo Therapeutics, Inc. and Subsidiaries (the “Company” or “ETI”) is primarily focused in the business of biomedical research and development, particularly in regenerative medicine, which has included the development of its proprietary non-invasive electroceutical™ device. Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation. Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $1,357,500 in debt and equity financing for the period January 1, 2018 to June 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates. Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive. Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at June 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed. Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements. In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2018
Revenue Recognition [Abstract]
Revenue Recognition	2. Revenue Recognition Contracts with Customers We have adopted ASC 606, Revenue from Contracts with Customers . Revenue Recognition We routinely plan on entering into contracts with customers that include general commercial terms and conditions, notification requirements for price increases, shipping terms and in most cases prices for the products and services that we offer. Our performance obligations are established when a customer submits a purchase order notification (in writing, electronically or verbally) for goods and services, and we accept the order. We identify performance obligations as the delivery of the requested product or service in appropriate quantities and to the location specified in the customer’s contract and/or purchase order. We generally recognize revenue upon the satisfaction of these criteria when control of the product or service has been transferred to the customer at which time we have an unconditional right to receive payment. Our sales and sale prices are final and our prices are not affected by contingent events that could impact the transaction price. Revenues for our SofPulse® product is typically recognized at the time the product is shipped, at which time the title passes to the customer, and there are no further performance obligations. In connection with offering products and services provided to the end user by third-party vendors, we review the relationship between us, the vendor and the end user to assess whether revenue should be reported on a gross or net basis. In asserting whether revenue should be reported on a gross or net basis, we consider whether we act as a principal in the transaction and control the goods and services used to fulfill the performance obligation(s) associated with the transaction. During the three months ended June 30, 2018, we recognized net revenues of $10,073 from products with a selling price of $21,023 and gross revenue of $2,781 from products we sold as a principal in the transaction. During the six months ended June 30, 2018, we recognized net revenue of $17,045 from products with a selling price of $43,196 and gross revenue of $2,781 from products we sold as a principal in the transaction. Sources of Revenue We have identified the following revenues disaggregated by revenue source: 1. Plastic Surgeons As of June 30, 2018 and 2017 the sources of revenue were as follows: Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Distributor- Plastic surgeons, net $ 10,073 $ - $ 17,045 $ - Direct sales- Plastic surgeons, gross 2,781 - 2,781 - Total sources of revenue $ 12,854 $ - $ 19,826 $ - Warranty Our general product warranties do not extend beyond an assurance that the product delivered will be consistent with stated specifications and do not include separate performance obligations. Significant Judgments in the Application of the Guidance in ASC 606 There are no significant judgments associated with the satisfaction of our performance obligations. We generally satisfy performance obligations upon delivery of the product to the customer. This is consistent with the time in which the customer obtains control of the products. Performance obligations are also generally settled quickly after the purchase order acceptance, therefore the value of unsatisfied performance obligations at the end of any reporting period is generally immaterial. We consider variable consideration in establishing the transaction price. Forms of variable consideration applicable to our arrangements include sales returns, rebates, volume-based bonuses, and prompt pay discounts. We use historical information along with an analysis of the expected value to properly calculate and to consider the need to constrain estimates of variable consideration. Such amounts are included as a reduction to revenue from the sale of products in the periods in which the related revenue is recognized and adjusted in future periods as necessary. Practical Expedients Our payment terms for sales direct to distributors are substantially less than the one-year collection period that falls within the practical expedient in determination of whether a significant financing component exists. Taxes Collected from Customers Taxes collected on the value of transaction revenue are excluded from product revenues and are accrued in current liabilities until remitted to governmental authorities. Effective Date and Transition Disclosures Adoption of the new standards related to revenue recognition did not have a material impact on our consolidated financial statements.

Property, Plant and Equipment

Property, Plant and Equipment	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Note 3 – Property, Plant and Equipment The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Autos $ 64,458 $ 64,458 Medical equipment 13,969 5,000 Other equipment 8,774 8,774 87,201 78,232 Less accumulated depreciation 78,447 77,168 $ 8,754 $ 1,064 Depreciation expense for the six months ended June 30, 2018 and 2017 was $1,279 and $7,381, respectively. Repairs and maintenance are charged to expense as incurred while improvements are capitalized. Upon the sale, retirement or disposal of fixed assets, the accounts are relieved of the cost and the related accumulated depreciation with any gain or loss recorded to the consolidated statements of operations.

Patents

Patents	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	Note 4 – Patents In December 2017, we acquired from Rio Grande Neurosciences, Inc. (RGN) a patent portfolio for $4,500,000 as part of a settlement agreement. The oldest patents expire in 2024. The patent portfolio is amortized through 2024. The following is a summary of patents less accumulated amortization at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 323,455 - $ 4,176,545 $ 4,500,000 Amortization expense associated with patents was $323,455 and $0 for the six months ended June 30, 2018 and 2017. The estimated future amortization expense related to patents as of June 30, 2018 is as follows: Twelve Months Ending June 30, Amount 2019 $ 646,910 2020 646,910 2021 646,910 2022 646,910 2023 646,910 Thereafter 941,995 Total $ 4,176,545

Notes Payable and Long Term Loa

Notes Payable and Long Term Loan	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Notes Payable and Long Term Loan	Note 5 - Notes Payable and Long Term Loan Notes Payable During the six months ended June 30, 2018, the Company issued two Convertible Notes (“Variable Notes”) totaling $367,370 for funding of $325,000 with an original terms of one year with interest rates of 10%, and a variable conversion rates with discounts of 35% of the Company’s common stock based on the terms included in the Variable Note. The Variable Notes contains a prepayment option, which enables the Company to prepay the note subsequent to issuance at a premiums of 135%. The Company also issued two Fixed Rate Notes (“Fixed Rate Notes”) totaling $583,000 for funding of $500,000 with an original term of six months and an interest rate of 12%. The gross amount of all convertible notes with variable conversion rates outstanding at June 30, 2018 is $4,116,120, of which $1,528,750 are past maturity. Notes payable to a related party in the aggregate amount of $270,000 were outstanding at June 30, 2018. As of June 30, 2018, other notes payable outstanding totaled $3,102,903, of which $919,903 are past maturity. June 30, 2018 December 31, 2017 Notes payable at beginning of period $ 7,356,144 $ 3,193,956 Notes payable issued 950,370 5,837,070 Settlements on note payable (47,500 ) (95,597 ) Repayments of notes payable in cash (12,500 ) (96,000 ) Less amounts converted to stock (757,491 ) (1,483,285 ) Notes payable at end of period 7,489,023 7,356,144 Less debt discount (1,355,554 ) (2,624,984 ) $ 6,133,469 $ 4,731,160 Notes payable issued to related parties $ 270,000 $ 270,000 Notes payable issued to non-related parties $ 5,863,469 $ 4,461,160 The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 2,448,653 $ - $ 2,448,653 June 30, 2019 4,770,370 270,000 5,040,370 Total $ 7,219,023 $ 270,000 $ 7,489,023

Shareholders' Deficit

Shareholders' Deficit	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Shareholders' Deficit	Note 6 - Shareholders’ Deficit Preferred Stock The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Authorized Number of Shares Outstanding at June 30, 2018 Par Value Liquidation Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 1,350 $ 0.0001 $ 100 Preferred Series C 8,000 1,037 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - - Series AA Preferred Shares On February 22, 2013, the Board of Directors of the Company authorized an amendment to the Company’s Articles of Incorporation, as amended (the “Articles of Incorporation”), in the form of a Certificate of Designation that authorized the issuance of up to one million (1,000,000) shares of a new series of preferred stock, par value $0.0001 per share, designated “Series AA Super Voting Preferred Stock,” for which the board of directors established the rights, preferences and limitations thereof. Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company. The Series AA Super Voting Preferred Stock holders will receive no dividends nor any value on liquidation. As of June 30, 2018, there were 5,000 shares of Series AA Preferred stock outstanding. Series B Convertible Preferred Stock On February 7, 2017, the Company filed a certificate of designation for 50,000 shares of Series B Convertible Preferred Stock designated as Series B (“Series B”) which are authorized and convertible, at the option of the holder, commencing six months from the date of issuance into common shares and warrants. For each share of Series B, the holder, on conversion, shall receive the stated value divided by 75% of the market price on the date of purchase of Series B and a three-year warrant exercisable into up to a like amount of common shares with an exercise price of 150% of the market price as defined in the Certificate of Designation. Dividends shall be paid only if dividends on the Company’s issued and outstanding Common Stock are paid and the amount paid to the Series B holder will be as though the conversion shares had been issued. The Series B holders have no voting rights. Upon liquidation, the holder of Series B, shall be entitled to receive an amount equal to the stated value, $100 per share, plus any accrued and unpaid dividends thereon before any distribution is made to Series C Secured Redeemable Preferred Stock or common stockholders. As of June 30, 2018, 1,350 shares of Series B and 4,805,600 warrant shares have been issued and are outstanding. Series C Secured Redeemable Preferred Stock On December 22, 2017, the Company filed a certificate of designation for 8,000 shares of Series C Secured Redeemable Preferred Stock (“Series C”). Each share of the C Preferred is entitled to receive a $20.00 quarterly dividend commencing March 31, 2018 and each quarter thereafter and is to be redeemed for the stated value, $1,000 per share, plus accrued dividends in cash (i) at the Company’s option, commencing one year from issuance and (ii) mandatorily as of December 31, 2019. The C Preferred does not have any rights to vote with the common stock. Upon liquidation, the holder of Series C, shall be entitled to receive an amount equal to the stated value, $1,000 per share, plus any accrued and unpaid dividends thereon before any distribution is made to common stockholders but after distributions are made to holders of Series B. Since the C Preferred is mandatorily payable, the obligation has been included in long term liabilities on the consolidated balance sheets as of June 30, 2018 and December 31, 2017. The Company’s obligation to redeem the C Preferred is secured by a security interest in the RGN Assets. As of June 30, 2018, the Company has sold 1,037 shares of C Preferred in units comprised of shares of C Preferred and common stock purchase warrants exercisable into up to 4,490,738 shares of common stock for consideration of $1,037,500. The warrants resulted in a debt discount of $115,596 and $101,808 at June 30, 2018 and December 31, 2017, respectively, and are recorded as a discount to the preferred stock liability on the consolidated balance sheet. Common Stock During the six months ended June 30, 2018, the Company issued pursuant to a private placement offering 1,561,950 shares of common stock and the same number of warrants for cash of $60,000. The Company also issued 34,225,740 shares of common stock for the conversion of notes and accrued interest in the amount of $824,053. During the six months ended June 30, 2018, the Company issued 17,003 shares of common stock valued at $1,046 related to the extension of outstanding notes and lock-up agreements. During the six months ended June 30, 2018, the Company issued 125,000 shares of common stock with a value of $5,460, related to services and fees. During the six months ended June 30, 2018, the Company issued 3,387,534 shares of common stock with a value of $116,531 as a commitment to repay a note payable on its stated terms. If the note is satisfactorily repaid, the shares shall be rescinded. Until it is determined if the terms of the note will be met, the value of the shares is being reflected as a discount to the note. The Variable Debentures issued by the Company each have a provision requiring the Company to reserve a variable amount of shares of common stock for when the holder of the Variable Debenture converts. Stock Options The balance of all stock options outstanding as of June 30, 2018 is as follows: Weighted Average Exercise Price Weighted Average Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96 Granted - $ - Cancelled - $ - Exercised - $ - Outstanding at June 30, 2018 93,203,369 $ 0.029 3.46 $ 624,463 Exercisable at June 30, 2018 93,203,369 $ 0.029 3.46 $ 624,463 Warrants During the six months ended June 30, 2018, in conjunction with the sale of Common Stock, the Company issued three-year common stock purchase warrants to acquire up to 1,561,950 shares of common stock with exercise prices ranging from $0.0734 to $1.00 per share. In addition, during the six months ended June 30, 2018, the Company issued a five-year common stock purchase warrant to acquire up to 2,000,000 shares of common stock valued at $71,521 with an exercise price of $0.05 in conjunction with the issuance of a note payable; three-year common stock purchase warrants to acquire up to 4,805,600 shares of common stock with exercise prices ranging from $0.051 to $1.00 in conjunction with the issuance of Series B preferred stock; two-year common stock purchase warrants to acquire up to 1,765,469 shares of common stock with exercise prices ranging from $0.0355 to $0.0516 in conjunction with the issuance of Series C preferred stock; a 2-year common stock purchase warrant to acquire up to 6,200,000 shares of common stock valued at $380,750 with an exercise price of $0.0001; and two-year common stock purchase warrants to acquire up to 642,157 shares of common stock with exercise prices ranging from $0.0368 to $0.0370 in conjunction with the extension of certain notes payable. The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2018 Expected term 2 years - 5 years Exercise price $0.0001-$0.0516 Expected volatility 166%-193 % Expected dividends None Risk-free interest rate 1.92% to 2.65 % Forfeitures None A summary of the status of the warrants granted under these agreements at June 30, 2018, and changes during the three months then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2018 61,807,992 $ 0.31 Granted 16,975,176 $ 0.21 Cancelled (300,000 ) $ 0.81 Exercised - $ - Outstanding at June 30, 2018 78,483,168 $ 0.29 Exercisable at June 30, 2018 78,483,168 $ 0.29 As of June 30, 2018, the Company has 500,000,000 shares of common stock authorized. After the exercise of stock options and warrants and the conversion of variable rate debentures, the Company could potentially have a shortfall of common stock. Should there be a shortfall in common stock, the shareholders of the Company would need to approve an increase in the authorized common stock to an amount sufficient to satisfy such exercises and conversions or reclassify the obligations to liabilities payable in some form other than common stock.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2018
Related Party Transactions [Abstract]
Related Party Transactions	Note 7 – Related Party Transactions One executive of the Company has entered into note payable agreements with the Company. The balance of notes payable from related parties at June 30, 2018 is $270,000. As of June 30, 2018 and December 31, 2017, the balance of executives’ deferred compensation is $968,150 and $922,425, respectively. From time-to-time executives of the Company advance monies to the Company to cover costs. During the three months ended June 30, 2018, executives advanced $65,000 of funds to the Company and received payments of $87,000 resulting in a $0 balance of short-term advances due to executives at June 30, 2018.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 8 – Fair Value Measurements The Company has issued Variable Debentures which contained variable conversion rates based on unknown future prices of the Company’s common stock. This results in a conversion feature. The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2018 2017 Expected term 1 month - 1 year 8 months - 5 years Exercise price $0.0195-$0.0326 $0.0203-$0.28 Expected volatility 127%-195% 184%-276% Expected dividends None None Risk-free interest rate 1.79% to 2.35% 0.45% to 1.79% Forfeitures None None The assumptions used in determining fair value represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. As a result, if factors change, including changes in the market value of the Company’s common stock, managements’ assessment or significant fluctuations in the volatility of the trading market for the Company’s common stock, the Company’s fair value estimates could be materially different in the future. The Company computes the fair value of the derivative liability at each reporting period and the change in the fair value is recorded as non-cash expense or non-cash income. The key component in the value of the derivative liability is the Company’s stock price, which is subject to significant fluctuation and is not under its control. The resulting effect on net loss is therefore subject to significant fluctuation and will continue to be so until the Company’s Variable Debentures, which the convertible feature is associated with, are converted into common stock or paid in full with cash. Assuming all other fair value inputs remain constant, the Company will record non-cash expense when its stock price increases and non-cash income when its stock price decreases. The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2018: Derivative Liability Balance December 31, 2017 $ 5,939,600 Issuance of convertible debt 461,860 Settlements by debt settlement (820,357 ) Change in estimated fair value (2,461,179 ) Balance June 30, 2018 $ 3,119,924 Accounting guidance on fair value measurements and disclosures defines fair value, establishes a framework for measuring the fair value of assets and liabilities using a hierarchy system, and defines required disclosures. It clarifies that fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the reporting entity transacts business. The Company’s balance sheet contains derivative liabilities that are recorded at fair value on a recurring basis. The three-level valuation hierarchy for disclosure of fair value is as follows: Level 1: uses quoted market prices in active markets for identical assets or liabilities. Level 2: uses observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: uses unobservable inputs that are not corroborated by market data. The fair value of the Company’s recorded derivative liability is determined based on unobservable inputs that are not corroborated by market data, which require a Level 3 classification. A Black Scholes option pricing model was used to determine the fair value. The Company records derivative liability on the condensed consolidated balance sheets at fair value with changes in fair value recorded in the condensed consolidated statements of operation. The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at June 30, 2018: Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Total As of June 30, 2018 Derivative liability $ - $ - $ 3,119,924 $ 3,119,924 Total $ - $ - $ 3,119,924 $ 3,119,924

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 9 – Commitments and Contingencies Legal Matters The Company may become involved in various legal proceedings in the normal course of business.

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 10 – Subsequent Events Subsequent to June 30, 2018, an aggregate of 9,849,828 shares of restricted common stock were issued on the conversion of $175,000 of principal and $19,922 of accrued interest pursuant to one Variable Note. Subsequent to June 30, 2018, the Company received $175,000 of funding in connection with a $189,000 convertible note due on July 3, 2019 bearing interest at a rate of 10%. Subsequent to June 30, 2018, the Company received $144,000 of funding in connection with a $157,500 convertible note due on August 3, 2019 bearing interest at a rate of 10%. Subsequent to June 30, 2018, the Company received $130,000 of cash from the issuance of 130 shares of Preferred C Stock and issued two-year warrants for the exercise up to 756,068 shares of common stock with an exercise prices ranging from $0.0299 to $0.035. As a result of these issuances, the total number of common shares outstanding is 366,170,845, Preferred B shares outstanding is 1,350 and Preferred C shares outstanding is 1,168.

Organization and Nature of Bu17

Organization and Nature of Business (Policies)	6 Months Ended
	Jun. 30, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying unaudited interim condensed consolidated financial statements have been presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Article 8 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by GAAP for complete financial statements. The condensed consolidated financial statements as of June 30, 2018 and 2017 are unaudited; however, in the opinion of management such interim condensed consolidated financial statements reflect all adjustments, consisting solely of normal recurring adjustments, necessary for a fair presentation of the results for the periods presented. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto in the Company’s most recent Annual Report on Form 10-K, as filed with the Securities and Exchange Commission (the “SEC”) on April 6, 2018. The results of operations for the period presented are not necessarily indicative of the results that might be expected for future interim periods or for the full year. The consolidated financial statements of the Company include the accounts of ETI and IPR as of March 14, 2012; Aviva as of April 2, 2013; and WeHealAnimals as of November 16, 2013. All significant intercompany accounts and transactions are eliminated in consolidation.
Going Concern	Going Concern These accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates realization of assets and the satisfaction of liabilities in the normal course of business for the twelve month period following the date these consolidated financial statements are issued. The Company has raised approximately $1,357,500 in debt and equity financing for the period January 1, 2018 to June 30, 2018. The Company is raising additional capital through debt and equity securities in order to continue the funding of its operations. However, there is no assurance that the Company can raise enough funds or generate sufficient revenues to pay its obligations as they become due, which raises substantial doubt about our ability to continue as a going concern. No adjustments have been made to the carrying value of assets or liabilities as a result of this uncertainty. To reduce the risk of not being able to continue as a going concern, management is commercializing its FDA cleared and CE marked products and has partially implemented its business plan to materialize revenues from potential, future, license agreements, has initiated a private placement offering to raise capital through the sale of its preferred and common stock and is seeking out profitable companies.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Critical estimates include the value of shares issued for services, in connection with notes payable agreements, in connection with note extension agreements, and as repayment for outstanding debt, the useful lives of property and equipment, the valuation of the derivative liability, the valuation of warrants and stock options, and the valuation of deferred income tax assets. Management uses its historical records and knowledge of its business in making these estimates. Actual results could differ from these estimates.
Net Income (Loss) Per Share	Net Income (Loss) per Share Basic net income (loss) per share is calculated based on the net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding for the period excluding any dilutive effects of options, warrants, unvested share awards and convertible securities. Diluted net income (loss) per common share assumes the conversion of all dilutive securities using the if-converted method and assumes the exercise or vesting of other dilutive securities, such as options, common shares issuable under convertible debt, warrants and restricted stock using the treasury stock method when dilutive.
Accounts Receivable	Accounts Receivable The Company uses the specific identification method for recording the provision for doubtful accounts, which was $0 at June 30, 2018 and December 31, 2017. Accounts receivable are written off when all collection attempts have failed.
Research and Development	Research and Development Costs relating to the development of new products are expensed as research and development as incurred in accordance with FASB Accounting Standards Codification (“ASC”) 730-10, Research and Development
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes existing guidance on accounting for leases in “Leases (Topic 840)” and generally requires all leases to be recognized in the consolidated balance sheet. ASU 2016-02 is effective for annual and interim reporting periods beginning after December 15, 2018; early adoption is permitted. The provisions of ASU 2016-02 are to be applied using a modified retrospective approach. The Company does not expect the adoption of this standard to significantly impact its consolidated financial statements. In 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments Restricted Cash In 2016, the FASB issued ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory On January 1, 2017, we adopted ASU 2016-09, Compensation - Stock Compensation In January 2017, the FASB issued ASU 2017-01, Business Combinations (“ASU 2017-01”) which provided new guidance clarifying the definition of a business for determining whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. The new standard is effective for annual periods, and interim periods within those annual periods, beginning after December 15, 2017 with early adoption permitted for transactions that occurred before the issuance date or effective date of the standard if the transactions were not reported in financial statements that have been issued or made available for issuance. Upon early adoption, the standard did not impact how we assess acquisitions (or disposals) of assets or businesses. In January 2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other (Topic 350) that simplifies the test for goodwill impairment by eliminating step two from the goodwill impairment test. Under the new guidance, an entity should recognize an impairment charge for the amount based on the excess of a reporting unit’s carrying amount over its fair value. The impairment charge will be limited to the amount of goodwill allocated to that reporting unit. For public companies, the guidance is effective for annual and interim impairment tests performed in periods beginning after December 15, 2019 on a prospective basis, and earlier adoption is permitted for goodwill impairment tests performed on testing dates after January 1, 2017. We early adopted this guidance during the three months ended March 2017, and the adoption did not impact our financial statements. In May 2014, the FASB issued ASU 2014-09 and modified the standard thereafter within Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions resulting from expanding the scope of Topic 718, Compensation—Stock Compensation, to include share-based payment transactions for acquiring goods and services from nonemployees. This ASU is effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted, but no earlier than an entity’s adoption date of Topic 606. The Company is currently evaluating the impact of the new guidance on our consolidated financial statements. In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases. The amendments in this Update affect the amendments in Update 2016-02, which are not yet effective, but for which early adoption upon issuance is permitted. For entities that early adopted Topic 842, the amendments are effective upon issuance of this Update, and the transition requirements are the same as those in Topic 842. For entities that have not adopted Topic 842, the effective date and transition requirements will be the same as the effective date and transition requirements in Topic 842. The Company has not yet selected a transition method nor has it determined the effect of the standard on its ongoing financial reporting. The Company has evaluated all the recent accounting pronouncements and determined that there are no other accounting pronouncements that will have a material effect on the Company’s financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2018
Revenue Recognition [Abstract]
Schedule of Disaggregated by Revenue Source	As of June 30, 2018 and 2017 the sources of revenue were as follows: Three Months Ended Six Months Ended June 30, June 30, 2018 2017 2018 2017 Distributor- Plastic surgeons, net $ 10,073 $ - $ 17,045 $ - Direct sales- Plastic surgeons, gross 2,781 - 2,781 - Total sources of revenue $ 12,854 $ - $ 19,826 $ -

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	6 Months Ended
	Jun. 30, 2018
Property, Plant and Equipment [Abstract]
Summary of Property, Plant and Equipment	The following is a summary of equipment, at cost, less accumulated depreciation at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Autos $ 64,458 $ 64,458 Medical equipment 13,969 5,000 Other equipment 8,774 8,774 87,201 78,232 Less accumulated depreciation 78,447 77,168 $ 8,754 $ 1,064

Patents (Tables)

Patents (Tables)	6 Months Ended
	Jun. 30, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Patents Less Accumulated Amortization	The following is a summary of patents less accumulated amortization at June 30, 2018 and December 31, 2017: June 30, 2018 December 31, 2017 Patents $ 4,500,000 $ 4,500,000 Less accumulated amortization 323,455 - $ 4,176,545 $ 4,500,000
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense related to patents as of June 30, 2018 is as follows: Twelve Months Ending June 30, Amount 2019 $ 646,910 2020 646,910 2021 646,910 2022 646,910 2023 646,910 Thereafter 941,995 Total $ 4,176,545

Notes Payable and Long Term L21

Notes Payable and Long Term Loan (Tables)	6 Months Ended
	Jun. 30, 2018
Debt Disclosure [Abstract]
Schedule of Notes Payable	As of June 30, 2018, other notes payable outstanding totaled $3,102,903, of which $919,903 are past maturity. June 30, 2018 December 31, 2017 Notes payable at beginning of period $ 7,356,144 $ 3,193,956 Notes payable issued 950,370 5,837,070 Settlements on note payable (47,500 ) (95,597 ) Repayments of notes payable in cash (12,500 ) (96,000 ) Less amounts converted to stock (757,491 ) (1,483,285 ) Notes payable at end of period 7,489,023 7,356,144 Less debt discount (1,355,554 ) (2,624,984 ) $ 6,133,469 $ 4,731,160 Notes payable issued to related parties $ 270,000 $ 270,000 Notes payable issued to non-related parties $ 5,863,469 $ 4,461,160
Schedule of Maturity Dates of Notes Payable	The maturity dates on the notes payable are as follows: Twelve months ending, Non-related parties Related parties Total Past due $ 2,448,653 $ - $ 2,448,653 June 30, 2019 4,770,370 270,000 5,040,370 Total $ 7,219,023 $ 270,000 $ 7,489,023

Shareholders' Deficit (Tables)

Shareholders' Deficit (Tables)	6 Months Ended
	Jun. 30, 2018
Equity [Abstract]
Schedule of Preferred Stock	The Company has authorized 5,000,000 shares of preferred stock which have been designated as follows: Number of Shares Authorized Number of Shares Outstanding at June 30, 2018 Par Value Liquidation Value Series AA 1,000,000 5,000 $ 0.0001 $ - Preferred Series B 50,000 1,350 $ 0.0001 $ 100 Preferred Series C 8,000 1,037 $ 0.0001 $ 1,000 Undesignated 3,942,000 - - -
Schedule of Stock Options Outstanding	The balance of all stock options outstanding as of June 30, 2018 is as follows: Weighted Average Exercise Price Weighted Average Remaining Contractual Aggregate Intrinsic Options Per Share Term (years) Value Outstanding at January 1, 2018 93,203,369 $ 0.029 3.96 Granted - $ - Cancelled - $ - Exercised - $ - Outstanding at June 30, 2018 93,203,369 $ 0.029 3.46 $ 624,463 Exercisable at June 30, 2018 93,203,369 $ 0.029 3.46 $ 624,463
Schedule of Stock Options Valuation of Assumptions	The Company measures the fair value of warrants issued using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2018 Expected term 2 years - 5 years Exercise price $0.0001-$0.0516 Expected volatility 166%-193 % Expected dividends None Risk-free interest rate 1.92% to 2.65 % Forfeitures None
Schedule of Warrants Outstanding	A summary of the status of the warrants granted under these agreements at June 30, 2018, and changes during the three months then ended is presented below: Outstanding Warrants Weighted Average Exercise Price Shares Per Share Outstanding at January 1, 2018 61,807,992 $ 0.31 Granted 16,975,176 $ 0.21 Cancelled (300,000 ) $ 0.81 Exercised - $ - Outstanding at June 30, 2018 78,483,168 $ 0.29 Exercisable at June 30, 2018 78,483,168 $ 0.29

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2018
Fair Value Disclosures [Abstract]
Schedule of Stock Option Valuation Assumptions	The Company measures the conversion feature using the Black Scholes option pricing model using the following assumptions: Six months ended June 30, 2018 2017 Expected term 1 month - 1 year 8 months - 5 years Exercise price $0.0195-$0.0326 $0.0203-$0.28 Expected volatility 127%-195% 184%-276% Expected dividends None None Risk-free interest rate 1.79% to 2.35% 0.45% to 1.79% Forfeitures None None
Schedule of Changes in Liabilities with Significant Unobservable Inputs	The following table presents changes in the liabilities with significant unobservable inputs (level 3) for the six months ended June 30, 2018: Derivative Liability Balance December 31, 2017 $ 5,939,600 Issuance of convertible debt 461,860 Settlements by debt settlement (820,357 ) Change in estimated fair value (2,461,179 ) Balance June 30, 2018 $ 3,119,924
Schedule of Balance in Liabilities with Significant Unobservable Inputs	The following table presents balances in the liabilities with significant unobservable inputs (Level 3) at June 30, 2018: Fair Value Measurements Using Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs (Level 1) (Level 2) (Level 3) Total As of June 30, 2018 Derivative liability $ - $ - $ 3,119,924 $ 3,119,924 Total $ - $ - $ 3,119,924 $ 3,119,924

Organization and Nature of Bu24

Organization and Nature of Business (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Debt and equity financing			$ 1,357,500
Provision for doubtful accounts	$ 0		0		$ 0
Research and development expenses	$ 43,727	$ 0	$ 157,835	$ 0

Revenue Recognition (Details Na

Revenue Recognition (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Recognized net revenues	$ 12,854		$ 19,826
Product [Member]
Recognized net revenues	10,073		17,045
Selling price	21,023		43,196
Gross Revenue [Member]
Recognized net revenues	$ 2,781		$ 2,781

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Disaggregated by Revenue Source (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Total sources of revenue	$ 12,854		$ 19,826
Distributor Plastic Surgeons Net [Member]
Total sources of revenue	10,073		17,045
Direct Sales Plastic Surgeons Gross [Member]
Total sources of revenue	$ 2,781		$ 2,781

Property, Plant and Equipment27

Property, Plant and Equipment (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 1,279	$ 7,381

Property, Plant and Equipment -

Property, Plant and Equipment - Summary of Property, Plant and Equipment (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, gross	$ 87,201	$ 78,232
Less accumulated depreciation	78,447	77,168
Property, Plant and Equipment, net	8,754	1,064
Autos [Member]
Property, Plant and Equipment, gross	64,458	64,458
Medical Equipment [Member]
Property, Plant and Equipment, gross	13,969	5,000
Other Equipment [Member]
Property, Plant and Equipment, gross	$ 8,774	$ 8,774

Patents (Details Narrative)

Patents (Details Narrative) - USD ($)	1 Months Ended	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2018	Jun. 30, 2017
Amortization expense		$ 323,455	$ 0
Settlement Agreement [Member] | Rio Grande Neurosciences, Inc. [Member]
Acquisition of patents	$ 4,500,000
Patents expire period	2,024
Patent amortization description	Patent portfolio is amortized through 2024

Patents - Schedule of Patents L

Patents - Schedule of Patents Less Accumulated Amortization (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Patents	$ 4,500,000	$ 4,500,000
Less accumulated amortization	323,455
Total	$ 4,176,545	$ 4,500,000

Patents - Schedule of Estimated

Patents - Schedule of Estimated Future Amortization Expense (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
2,019	$ 646,910
2,020	646,910
2,021	646,910
2,022	646,910
2,023	646,910
Thereafter	941,995
Total	$ 4,176,545	$ 4,500,000

Notes Payable and Long Term L32

Notes Payable and Long Term Loan (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Note payable outstanding	$ 5,863,469		$ 4,461,160
Note payable related parties	270,000		$ 270,000
Payments for notes payable	12,500	$ 30,000
Convertible Debentures [Member]
Convertible debentures outstanding amount	$ 367,370
Debt instrument, interest rates	10.00%
Debt conversion, converted instrument, rates	35.00%
Percentage of issuance note of premium	135.00%
One Convertible Debentures [Member]
Convertible debentures outstanding amount	$ 325,000
Fixed Rate Note [Member]
Convertible debentures outstanding amount	$ 583,000
Debt instrument, interest rates	12.00%
One Fixed Rate Note [Member]
Convertible debentures outstanding amount	$ 500,000
Convertible Notes With Variable Conversion Rates [Member]
Note payable outstanding	4,116,120
Convertible Notes With Variable Conversion Rates [Member] | Past Maturity [Member]
Note payable outstanding	1,528,750
Other Notes Payable [Member]
Other notes payable outstanding	3,102,903
Other Notes Payable [Member] | Past Maturity [Member]
Other notes payable outstanding	$ 919,903

Notes Payable and Long Term L33

Notes Payable and Long Term Loan - Schedule of Notes Payable (Details) - USD ($)	6 Months Ended		12 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Repayments of notes payable in cash	$ (12,500)	$ (30,000)
Less amounts converted to stock	(1,468,064)
Notes Payable [Member]
Notes payable at beginning of period	7,356,144	$ 3,193,956	$ 3,193,956
Notes payable issued	950,370		5,837,070
Settlements on note payable	(47,500)		(95,597)
Repayments of notes payable in cash	(12,500)		(96,000)
Less amounts converted to stock	(757,491)		(1,483,285)
Notes payable at end of period	7,489,023		7,356,144
Less debt discount	(1,355,554)		(2,624,984)
Note payable, net	6,133,469		4,731,160
Notes payable issued to related parties	270,000		270,000
Notes payable issued to non-related parties	$ 5,863,469		$ 4,461,160

Notes Payable and Long Term L34

Notes Payable and Long Term Loan - Schedule of Maturity Dates of Notes Payable (Details)	Jun. 30, 2018USD ($)
Past due	$ 2,448,653
June 30, 2019	5,040,370
Total	7,489,023
Non-Related Parties [Member]
Past due	2,448,653
June 30, 2019	4,770,370
Total	7,219,023
Related Parties [Member]
Past due
June 30, 2019	270,000
Total	$ 270,000

Shareholders' Deficit (Details

Shareholders' Deficit (Details Narrative) - USD ($)	Feb. 22, 2013	Jun. 30, 2018	Feb. 07, 2018	Dec. 31, 2017	Dec. 22, 2017	Feb. 07, 2017
Preferred stock, authorized	1,000,000	1,000,000		1,000,000
Preferred stock, par value	$ 0.0001	$ 0.001		$ 0.001
Preferred stock voting rights	Each holder of outstanding shares of Series AA Super Voting Preferred Stock shall be entitled to one hundred thousand (100,000) votes for each share of Series AA Super Voting Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.
Preferred stock, outstanding		5,000		5,000
Stated value dividend		0.00%
Preferred stock, shares issued		5,000		5,000
Shares issued for conversion of notes payable and accrued interest		$ 1,468,064
Issuance of common stock, value		$ 135,000
Issuance of common stock related to services and fees, shares		125,000
Issuance of common stock related to services and fees		$ 5,460
Shares issued for commitment fees, shares		3,387,534
Shares issued for commitment fees		$ 116,531
Common stock, shares authorized		500,000,000		500,000,000
Notes Payable [Member]
Debt discount		$ 1,355,554		$ 2,624,984
Shares issued for conversion of notes payable and accrued interest		$ 757,491		1,483,285
Lock-Up Agreement [Member]
Common stock, shares issued		17,003
Issuance of common stock, value		$ 1,046
Series AA Preferred Stock [Member]
Preferred stock, outstanding		5,000
Series B Convertible Preferred Stock [Member]
Preferred stock, authorized						50,000
Preferred stock, par value						$ 100
Preferred stock, outstanding		1,350
Stated value dividend			75.00%
Warrants term			3 years
Share exercise price			1.50
Preferred stock, shares issued		1,350
Common stock, shares issued		1,350
Shares issued for conversion of notes payable and accrued interest, shares
Shares issued for conversion of notes payable and accrued interest
Issuance of common stock, value		$ 1
Issuance of common stock related to services and fees, shares
Issuance of common stock related to services and fees
Shares issued for commitment fees, shares
Shares issued for commitment fees
Series C Secured Redeemable Preferred Stock [Member]
Preferred stock, authorized					8,000
Preferred stock dividend per share		$ 20
Shares issued, price per share					$ 1,000
Sale of stock for preferred stock		1,037
Sale of stock, consideration		$ 1,037,500
Debt discount		$ 115,596		$ 101,808
Series C Secured Redeemable Preferred Stock [Member] | Maximum [Member]
Warrants issued to purchase common stock		4,490,738
Common Stock [Member] | Private Placement [Member]
Common stock, shares issued		1,561,950
Number of warrants issued for cash		$ 60,000
Shares issued for conversion of notes payable and accrued interest, shares		34,225,740
Shares issued for conversion of notes payable and accrued interest		$ 824,053
Preferred Stock Designated [Member]
Preferred stock, authorized		5,000,000
Warrant [Member]
Preferred stock, outstanding		4,805,600
Stated value dividend		0.00%
Warrants term		3 years
Preferred stock, shares issued		4,805,600
Warrants issued to purchase common stock		1,561,950
Warrant [Member] | Maximum [Member]
Warrant exercise price		$ 1
Warrant [Member] | Minimum [Member]
Warrant exercise price		$ 0.0734
Warrant Two [Member]
Warrants term		5 years
Warrants issued to purchase common stock		2,000,000
Warrant exercise price		$ 0.05
Warrant value		$ 71,521
Warrant Three [Member]
Warrants term		3 years
Warrants issued to purchase common stock		4,805,600
Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Maximum [Member]
Warrant exercise price		$ 1
Warrant Three [Member] | Series B Convertible Preferred Stock [Member] | Minimum [Member]
Warrant exercise price		$ 0.051
Warrant Four [Member]
Warrants term		2 years
Warrants issued to purchase common stock		1,765,469
Warrant Four [Member] | Series C Preferred Stock [Member] | Maximum [Member]
Warrant exercise price		$ 0.0516
Warrant Four [Member] | Series C Preferred Stock [Member] | Minimum [Member]
Warrant exercise price		$ 0.0355
Warrant Five [Member]
Warrants term		2 years
Warrants issued to purchase common stock		6,200,000
Warrant exercise price		$ 0.0001
Warrant value		$ 380,750
Warrant Six [Member]
Warrants term		2 years
Warrants issued to purchase common stock		642,157
Warrant Six [Member] | Maximum [Member] | Notes Payable [Member]
Warrant exercise price		$ 0.0370
Warrant Six [Member] | Minimum [Member] | Notes Payable [Member]
Warrant exercise price		$ 0.0368

Shareholders' Deficit - Schedul

Shareholders' Deficit - Schedule of Preferred Stock (Details) - USD ($)	Jun. 30, 2018	Dec. 31, 2017	Feb. 22, 2013
Number of Shares Authorized	1,000,000	1,000,000	1,000,000
Number of Shares Outstanding	5,000	5,000
Par Value	$ 0.001	$ 0.001	$ 0.0001
Series AA [Member]
Number of Shares Authorized	1,000,000
Number of Shares Outstanding	5,000
Par Value	$ 0.0001
Liquidation Value
Preferred Stock B [Member]
Number of Shares Authorized	50,000
Number of Shares Outstanding	1,350
Par Value	$ 0.0001
Liquidation Value	$ 100
Preferred Stock C [Member]
Number of Shares Authorized	8,000
Number of Shares Outstanding	1,037
Par Value	$ 0.0001
Liquidation Value	$ 1,000
Undesignated [Member]
Number of Shares Authorized	3,942,000
Number of Shares Outstanding
Par Value
Liquidation Value

Shareholders' Deficit - Sched37

Shareholders' Deficit - Schedule of Stock Options Outstanding (Details)	6 Months Ended
	Jun. 30, 2018USD ($)$ / sharesshares
Equity [Abstract]
Stock Option Outstanding, Beginning Balance | shares	93,203,369
Stock Option Outstanding, Granted | shares
Stock Option Outstanding, Cancelled | shares
Stock Option Outstanding, Exercised | shares
Stock Option Outstanding, Ending Balance | shares	93,203,369
Stock Option Outstanding, Exercisable | shares	93,203,369
Weighted Average Exercise Price, Beginning Balance | $ / shares	$ 0.029
Weighted Average Exercise Price, Granted | $ / shares
Weighted Average Exercise Price, Cancelled | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares
Weighted Average Exercise Price, Ending Balance | $ / shares	0.029
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.029
Weighted Average Remaining Contractual Term (years), Outstanding Beginning	3 years 11 months 15 days
Weighted Average Remaining Contractual Term (years), Outstanding Ending	3 years 5 months 16 days
Weighted Average Remaining Contractual Term (years), Exercisable	3 years 5 months 16 days
Aggregated Intrinsic Value, Outstanding | $	$ 624,463
Aggregated Intrinsic Value, Exercisable | $	$ 624,463

Shareholders' Deficit - Sched38

Shareholders' Deficit - Schedule of Stock Options Valuation of Assumptions (Details)	6 Months Ended
	Jun. 30, 2018$ / shares
Expected dividends	0.00%
Warrant [Member]
Expected dividends	0.00%
Forfeitures	0.00%
Warrant [Member] | Minimum [Member]
Expected term	2 years
Exercise price	$ 0.0001
Expected volatility	166.00%
Risk-free interest rate	1.92%
Warrant [Member] | Maximum [Member]
Expected term	5 years
Exercise price	$ 0.0516
Expected volatility	193.00%
Risk-free interest rate	2.65%

Shareholders' Deficit - Sched39

Shareholders' Deficit - Schedule of Warrants Outstanding (Details) - Warrant [Member]	6 Months Ended
	Jun. 30, 2018$ / sharesshares
Shares Outstanding, Beginning Balance | shares	61,807,992
Shares, Granted | shares	16,975,176
Shares, Cancelled | shares	(300,000)
Shares, Exercised | shares
Shares Outstanding, Ending Balance | shares	78,483,168
Shares Exercisable, Ending Balance | shares	78,483,168
Weighted-Average Exercise Price, Outstanding Beginning Balance | $ / shares	$ 0.31
Weighted-Average Exercise Price, Granted | $ / shares	0.21
Weighted average exercise price, Cancelled | $ / shares	0.81
Weighted-Average Exercise Price, Exercised | $ / shares
Weighted-Average Exercise Price, Outstanding Ending Balance | $ / shares	0.29
Weighted-Average Exercise Price, Exercisable Ending Balance | $ / shares	$ 0.29

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017
Notes payable - related parties	$ 270,000		$ 270,000
Repayment of related party debt	87,000	$ 11,500
Executives [Member]
Deferred compensation	968,150		$ 922,425
Related party advances	65,000
Repayment of related party debt	87,000
Short-term advances	$ 0

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Stock Option Valuation Assumptions (Details) - $ / shares	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Forfeitures	0.00%	0.00%
Measurement Input, Expected Term [Member] | Minimum [Member]
Fair value assumptions, measurement input, term	1 month	8 months
Measurement Input, Expected Term [Member] | Maximum [Member]
Fair value assumptions, measurement input, term	1 year	5 years
Measurement Input, Exercise Price [Member] | Minimum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.0195	$ 0.0203
Measurement Input, Exercise Price [Member] | Maximum [Member]
Fair value assumptions, measurement input, exercise price	$ 0.0326	$ 0.28
Measurement Input, Price Volatility [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	127.00%	184.00%
Measurement Input, Price Volatility [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	195.00%	276.00%
Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentage	0.00%	0.00%
Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]
Fair value assumptions, measurement input, percentage	1.79%	0.45%
Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]
Fair value assumptions, measurement input, percentage	2.35%	1.79%

Fair Value Measurements - Sch42

Fair Value Measurements - Schedule of Changes in Liabilities with Significant Unobservable Inputs (Details)	6 Months Ended
	Jun. 30, 2018USD ($)
Derivative Liability, ending	$ 3,119,924
Significant Unobservable Inputs (Level 3) [Member]
Derivative Liability, beginning	5,939,600
Issuance of convertible debt	461,860
Settlements by debt settlement	(820,357)
Change in estimated fair value	(2,461,179)
Derivative Liability, ending	$ 3,119,924

Fair Value Measurements - Sch43

Fair Value Measurements - Schedule of Balance in Liabilities with Significant Unobservable Inputs (Details)	Jun. 30, 2018USD ($)
Derivative liability	$ 3,119,924
Total	3,119,924
Fair Value, Inputs, Level 1 [Member]
Derivative liability
Total
Fair Value, Inputs, Level 2 [Member]
Derivative liability
Total
Fair Value, Inputs, Level 3 [Member]
Derivative liability	3,119,924
Total	$ 3,119,924

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2018	Dec. 31, 2017
Issuance of restricted common stock, value	$ 1,468,064
Number of shares issued, value	$ 135,000
Two Year Warrant One [Member]
Warrants term	2 years
Warrant to purchase common stock	756,068
Two Year Warrant One [Member] | Minimum [Member]
Warrant exercise price	$ 0.0299
Two Year Warrant One [Member] | Maximum [Member]
Warrant exercise price	$ 0.035
Common Stock [Member]
Issuance of restricted common stock, shares	34,225,740
Issuance of restricted common stock, value	$ 3,423
Number of shares issued, value
Number of shares issued
Number of shares outstanding	366,118,767	316,951,712
Preferred B Stock [Member]
Number of shares outstanding	1,350
Preferred C Stock [Member]
Number of shares outstanding	1,168
Preferred C Stock [Member]
Number of shares issued, value	$ 130,000
Number of shares issued	130
Convertible Note [Member]
Proceeds from convertible note	$ 175,000
Convertible debt	$ 189,000
Debt instrument maturity date	Jul. 3, 2019
Debt instrument interest rate	10.00%
Convertible Note on August 3, 2019 [Member]
Proceeds from convertible note	$ 144,000
Convertible debt	$ 157,500
Debt instrument maturity date	Aug. 3, 2019
Debt instrument interest rate	10.00%
Restricted Common Stock [Member] | One Variable Note [Member]
Issuance of restricted common stock, shares	9,849,828
Issuance of restricted common stock, value	$ 175,000
Accrued interest	$ 19,922